Sorafenib Myths: — Dose Cuts, Last Resort, Generic Quality

My dose was cut — that means sorafenib has stopped working.

Dose reduction is a planned clinical tool, not a sign that treatment has failed. NCCN guidance describes dose modification as a standard part of sorafenib management. Your oncologist may reduce the dose to control side effects so you can continue treatment for longer. Staying on a lower dose consistently is better than stopping a full dose you cannot tolerate. Many people assume that less medicine means less effect, as they would with an antibiotic — with sorafenib, what matters is staying on it.

Sorafenib is a last resort, given only when everything else has failed.

For advanced liver cancer and kidney cancer, sorafenib is often among the first systemic treatments offered, not the last. NCCN and ESMO guidelines list it as a recommended option early in the treatment pathway for these cancers. It was one of the first targeted therapies to demonstrate benefit in hepatocellular carcinoma, which is why it holds an established early-line position. The assumption that oncologists hold the strongest medicines back is understandable — but it does not apply here.

The generic sorafenib here in India is not as strong as the original Nexavar.

CDSCO requires generic medicines to demonstrate bioequivalence to the originator before they can be approved for sale. For sorafenib, this means the generic must show it delivers the same amount of active drug into the bloodstream under the same conditions as Nexavar. The active molecule is chemically identical. What differs is the manufacturer, the brand name, the packaging and, often, the price. Generics look different and cost less — both of which create a feeling of lower quality. That feeling does not reflect what the drug actually contains.

Sorafenib is a type of chemotherapy.

Sorafenib is a targeted therapy — specifically a multi-kinase inhibitor. It works by blocking proteins that help tumour cells grow and form new blood vessels. Cytotoxic chemotherapy works by killing rapidly dividing cells throughout the body. The mechanism, the side effects, and the monitoring are all different. Sorafenib is taken as a tablet at home rather than given intravenously in a hospital. This distinction matters for understanding what your treatment is doing and for managing what it causes.

The hand-foot reaction means sorafenib is permanently damaging my skin.

Hand-foot skin reaction — redness, peeling and pain on the palms and soles — is a known and manageable side effect of sorafenib. It does not indicate lasting skin damage. Many people find it improves over time or after the dose is adjusted. It is uncomfortable and can be significant, but your oncology team has specific guidance for managing it. The reason it feels alarming is that it looks severe — but the appearance is more dramatic than the long-term consequence, provided it is reported promptly.